Caulley L, Eskander A, Yang W, Auh E, Cairncross L, Cho NL, Golbon B, Iyer S, Liu JC, Lee PJ, Lindeman B, Meltzer C, Molin N, Moore A, Noel J, Nozolino H, Pasternak J, Price B, Ramsay T, Rolighed L, Sajisevi M, Sharma A, Sinclair C, Sorensen M, Tae K, Tang AL, Tsao G, Williams M, Wrenn S, Xing MH, Zafereo ME , Stack BC, Randolph G, Davies L
The future oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other new oral metabolic products will become popular only if they prove themselves capable of producing sustained results in obesity disease, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risks, and metabolic syndromes through their effectiveness and safety
However, the long-term effect of GLP-1RAs on gastric emptying may not directly correlate with half-life
But after trying it, I reached my target weight of 136 lbs in 3 months
Lamia KA, Papp SJ, Yu RT, Barish GD, Uhlenhaut NH, Jonker JW, Downes M, Evans RM